High-dose, short-duration versus standard rifampicin for tuberculosis preventive treatment: a partially blinded, three-arm, non-inferiority, randomised, controlled trial-Reference-Cited by-同舟云学术

High-dose, short-duration versus standard rifampicin for tuberculosis preventive treatment: a partially blinded, three-arm, non-inferiority, randomised, controlled trial

Published:2024-06 Issue:6 Volume:12 Page:433-443
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Ruslami Rovina,Fregonese Federica,Apriani Lika,Barss Leila,Bedingfield Nancy,Chiang Victor,Cook Victoria J,Fisher Dina,Flores Eri,Fox Greg J,Johnston James,Lim Rachel K,Long Richard,Paulsen Catherine,Nguyen Thu Anh,Nhung Nguyen Viet,Gibson Diana,Valiquette Chantal,Benedetti Andrea,Menzies Dick

Publisher

Elsevier BV

Reference32 articles.

1. Global tuberculosis report 2022,2022

2. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling;Houben;PLoS Med,2016

3. Treatment of latent tuberculosis infection: an updated network meta-analysis;Zenner;Ann Intern Med,2017

4. Safety and side effects of rifampin versus isoniazid in children;Diallo;N Engl J Med,2018

5. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid;Villarino;JAMA Pediatr,2015

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics of standard versus high-dose rifampin for tuberculosis preventive treatment: A sub-study of the 2R2 randomized controlled trial;International Journal of Antimicrobial Agents;2024-07

2. High-dose rifampicin to treat tuberculosis infection: potential and pitfalls;The Lancet Respiratory Medicine;2024-06